 Phase 1 is an open label study to determine safety, tolerability of XPF-005 topical gel and exposure of XEN801 active ingredient. Four cohorts of 12 healthy volunteers will each receive different dose volumes of XPF-005 gel or Placebo gel on their face and back for 14 or 21 days. Safety assessments are completed and PK samples are collected at study visits. 